search button
Open Access

Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL‑23 and IL‑17A

  • Authors:
    • Yuming Kang
    • Guoai Su
    • Jianmin Sun
    • Yanli Zhang

  • View Affiliations

  • Published online on: April 26, 2018     https://doi.org/10.3892/ol.2018.8586
  • Pages: 9647-9654

  • Copyright: © Kang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Toll‑like receptor 4 (TLR4) and the interleukin (IL)‑23/IL‑17A axis serve an important role in tumor immunology. In the present study, the activation of the TLR4/myeloid differentiation primary response 88 (MyD88)‑mediated signal transduction pathway in human hepatocellular carcinoma (HCC) cells was examined using immunohistochemistry, and the association between TLR4 expression and the IL‑23/IL‑17A axis was detected by ELISA, reverse transcription‑quantitative polymerase chain reaction and western blot analysis in order to determine whether TLR4 and IL‑23/IL‑17A serve a role in HCC. It was observed that TLR4 expression was upregulated in HCC tissues compared with that in adjacent normal tissues. In addition, the TLR4 expression level was correlated with the degree of tumor differentiation and TNM stage. The expression levels of IL‑17A and IL‑23, which are key mediators of inflammation that contribute to carcinogenesis, are correlated with TLR4 expression in HCC. Cell line studies further revealed that activation of TLR4/MyD88 upregulated the expression of IL‑17A and IL‑23 at the mRNA and protein levels. Furthermore, activation of TLR4/MyD88 enhanced the expression of TLR4. IL‑17A and IL‑23 expression levels in HCC also appeared to be correlated with the TNM stage and tumor metastasis. In conclusion, the current results suggested that the TLR4/MyD88 signaling pathway is involved in HCC cell proliferation and metastasis via regulation of the IL‑23/IL‑17A axis; thus, the TLR4/IL‑23/IL‑17A pathway may represent a novel therapeutic target in HCC.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Kang Y, Su G, Sun J and Zhang Y: Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL‑23 and IL‑17A. Oncol Lett 15: 9647-9654, 2018.
APA
Kang, Y., Su, G., Sun, J., & Zhang, Y. (2018). Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL‑23 and IL‑17A. Oncology Letters, 15, 9647-9654. https://doi.org/10.3892/ol.2018.8586
MLA
Kang, Y., Su, G., Sun, J., Zhang, Y."Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL‑23 and IL‑17A". Oncology Letters 15.6 (2018): 9647-9654.
Chicago
Kang, Y., Su, G., Sun, J., Zhang, Y."Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL‑23 and IL‑17A". Oncology Letters 15, no. 6 (2018): 9647-9654. https://doi.org/10.3892/ol.2018.8586